Navidea Biopharmaceuticals CEO Jed Latkin's 2019 pay rises 16% to $740K
Navidea Biopharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: August 2, 2021
Navidea Biopharmaceuticals reported fiscal year 2019 executive compensation information on August 2, 2021.
In 2019, three executives at Navidea Biopharmaceuticals received on average a compensation package of $422K, a 22% decrease compared to previous year.
Average pay of disclosed executives at Navidea Biopharmaceuticals
Jed A. Latkin, Chief Executive Officer, received $740K in total, which increased by 16% compared to 2018. 64% of Latkin's compensation, or $475K, was in salary. Latkin also received $178K in non-equity incentive plan, $81K in option awards, as well as $5.6K in other compensation.
Joel H. Kaufman, Chief Business Officer, received a compensation package of $275K, which decreased by 12% compared to previous year. 82% of the compensation package, or $225K, was in salary.
Michael S. Rosol, Chief Medical Officer, earned $250K in 2019, a 2077% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on August 2, 2021.